#Italy #Bond Issuance #FIS #Montecchio Maggiore #Fabbrica Italiana Sintetici

FIS Achieves Major Milestone with €770 Million Bond Issuance

On February 5, 2026, FIS (Fabbrica Italiana Sintetici), a prominent company in the pharmaceutical sector, successfully finalized its issuance of €770 million in senior secured notes. This significant financial undertaking illustrates the unwavering confidence of investors in FIS’s growth strategy and operational integrity.

Overview of the Bond Issuance

The transaction was composed of two key elements. FIS issued €300 million in fixed-rate senior secured notes with an annual interest rate of 5.250%, alongside €470 million in floating-rate notes that bear interest linked to the three-month Euribor rate plus 325 basis points. The total issuance has been registered on the Luxembourg Stock Exchange, facilitating its trading on the Euro MTF Market.

The maturity date for the notes is set for February 2031, marking a five-year commitment that allows FIS to manage its long-term financing effectively.

Investor Sentiment and Market Response

The bond offering was oversubscribed, demonstrating robust demand from institutional investors. Strong interest signals the market's favorable view of FIS's financial health and strategic direction. Daniele Piergentili, the CEO and Chairman of FIS, expressed satisfaction with the positive reception to the bond issuance, underlining it as a validation of their business model.

In conjunction with the bond issuance, FIS revamped its existing revolving credit facility, increasing it from €80 million to €160 million. This adjustment not only enhances liquidity but also grants FIS additional financial leeway to navigate future expansions or investments.

Upgraded Credit Ratings

In light of this bond issuance, FIS’s financial profile received a boost from multiple credit rating agencies. Moody's upgraded their Corporate Family Rating from B3 to B2, while Fitch Ratings elevated their Issuer Default Rating from B to B+. Furthermore, Standard and Poor's maintained an Issuer Credit Rating of B, reaffirming the company's stable financial outlook.

These ratings reflect an increasing confidence in FIS's financial position and operational capabilities, positioning the company favorably within the competitive landscape of active pharmaceutical ingredient (API) production in Europe.

About FIS

Founded in 1957 and headquartered in Montecchio Maggiore, Italy, FIS has established itself as a key player in the pharmaceutical industry, particularly in the development and manufacturing of APIs. The firm operates three manufacturing sites across Italy, with international offices in North America and Japan, and production facilities in China and India. With a workforce of over 2,300 employees, FIS is recognized as an industry leader and has become a reliable partner in the Contract Development and Manufacturing Organization sector.

As FIS looks toward the future, the successful bond issuance not only enhances their financial standing but also signals potential growth opportunities driven by increased investment in research and development activities.

Conclusion

The completion of the €770 million bond issuance marks a pivotal moment for FIS. With strong investor interest and improved credit ratings, the company is well-positioned to capitalize on its strategic goals and reinforce its leadership in the pharmaceutical manufacturing landscape.